Water and environmental testing technology group Metir (LSE:MET) has warned that it would enter an Insolvency process "almost immediately" if it cannot raise money or secure extra Working Capital in the near term, after first-half Revenue fell 60% and cash dropped to £188k.

What was announced

Metir plc (LSE:MET), which is quoted on AIM, published unaudited interim results for the six months ended 30 June 2026 on 28 September 2026. The results were accompanied by a stark Going Concern statement.

The board said: "In the event that a fundraising or access to additional working capital cannot be completed in the near term, it is likely that the Company would not be able to continue as a going concern. If the Company cannot continue as a going concern, it would enter an insolvency process almost immediately, and there would in all probability be no value for Shareholders once all liabilities had been settled."

The company described a fundraise as "an acute priority" and said one is planned. The size, structure, pricing and timing of any fundraise have not been disclosed.

The numbers

Revenue fell 60% to £367k (H1 2025: £919k). Gross Margin improved to 46.3% from 38.3%, but operating expenses rose to £713k from £656k. The adjusted EBITDA loss widened to £512k from £261k, and the loss per share was 0.21p (0.16p).

Cash stood at £313k at 30 June 2026, compared with £585k a year earlier, and had fallen to about £188k by 25 September 2026. Net Assets were £721k, down from £1,236k at 31 December 2025. The company said working capital was "constrained pending a fundraise".

Metir attributed the revenue decline to three factors: lower sales of Microtox instruments; a temporary interruption to QuickChek SRB production for quality control on antibody production; and the Middle East conflict, which delayed the Phase 1 handover of its continuous toxicity monitoring (CTM) project in Qatar and associated reagent sales.

Operational update

Despite the weaker half, the company reported commercial activity across its product lines. It has sold 19 Microtox LX systems so far in 2026 and issued 144 customer quotations, 83 of them for LX/FX instruments. The Qatar installation covers 27 units, with Phase 1 handover now expected in Q4 2026; the company said this should bring recurring consumables revenue of about £30,000 a month. A potential Phase 2 would add 17 systems, subject to tender. Streamline Hydro has been appointed distributor for Australia and New Zealand, and an agreement with Future Solutions Company will see the Microtox technology validated through KAUST for Saudi Arabia's National Water Company.

QuickChek SRB production is due to restart in October 2026, with outstanding quotations for more than 20,500 kits, which the company values at about £1.23m at 2025 pricing. A mass production method is planned for Q1 2027.

In PFAS detection, Metir made a first commercial sale, on a lease-to-purchase basis, to Nasdaq-listed Veralto, completed field testing with ProDecon Services and agreed sole ownership of its PFAS measurement methodology. Phase 2 development of a Cryptosporidium pathogen detector with Aptamer Group is targeting commercialisation in early 2027.

What to watch next

Executive Chairman and Chief Executive Bob Moore said that, with delays pushing back sales, orders and revenue recognition, "the Board expects full-year revenue in 2026 to be lower than in 2025". He added that the board "is determined to complete a fundraise in the short term sufficient to enter 2027 with increasing confidence". The company said it believes 2027 "is capable of being a transformational year for the Group"; this is the company's own view, which it links to completing a fundraise.

The immediate milestone is therefore the outcome of the planned fundraise, followed by the QuickChek restart in October and the Qatar Phase 1 handover in the fourth quarter.